Glycemic Control Strategies in Type 2 Diabetes Management

Type 2 diabetes management centres on maintaining blood glucose within defined targets to minimise the risk of microvascular and macrovascular complications. Core strategies combine lifestyle modifications—principally structured dietary regimens, regular physical activity and weight management—with pharmacotherapy tailored to individual pathophysiology and comorbidities. First-line agents such as metformin are complemented by sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, each offering distinct glycaemic and extra-glycaemic benefits. Insulin therapy remains indispensable across disease stages. Self-monitoring of blood glucose and continuous glucose monitoring systems facilitate real-time feedback and dose titration. Recent advances in digital health platforms and telemedicine extend self-management support and personalised care. A cohesive, patient-centred approach integrating behavioural, technological and pharmacological interventions underpins optimal glycaemic control and reduces long-term morbidity.

Research from Nature Portfolio

A large cross-sectional study in Bangladesh found that over 80% of adults with type 2 diabetes failed to achieve HbA1c targets (≥7%), with more than half exhibiting very poor control (≥9%). Low educational attainment, rural residence and unhealthy eating habits were strongly associated with suboptimal control. Insulin use and infrequent clinical follow-up emerged as further risk factors, while comorbid coronary artery disease and cognitive impairment correlated with the most severe glycaemic derangement. The study highlights the necessity of tailored interventions addressing sociodemographic disparities, reinforcing lifestyle modification and ensuring timely therapeutic adjustments through enhanced patient–provider engagement.

Glycemic Control Strategies in Type 2 Diabetes Management publication trend

The graph below shows the total number of articles in glycemic control strategies in type 2 diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

Glycaemic control: Maintenance of blood glucose levels within a prescribed target range to prevent acute and chronic complications of diabetes.

HbA1c: Glycated haemoglobin representing average plasma glucose concentration over the preceding two to three months.

Sodium–glucose cotransporter 2 (SGLT2) inhibitor: A class of glucose-lowering agents that promote urinary glucose excretion by inhibiting renal glucose reabsorption.

Glucagon-like peptide 1 (GLP-1) receptor agonist: An incretin-based therapy that enhances insulin secretion, suppresses glucagon release and may aid weight loss.

Self-monitoring of blood glucose (SMBG): Regular, patient-initiated measurement of blood glucose to inform day-to-day management decisions.

References

1. Glycaemic Control for People with Type 2 Diabetes Mellitus in Bangladesh - An urgent need for optimization of management plan. Scientific Reports (2019).
2. Associations between adoption of eHealth management module and optimal control of HbA1c in diabetes patients. npj Digital Medicine (2023).
3. Determinants of poor glycemic control among type 2 diabetes mellitus patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: Unmatched case-control study. Frontiers in Endocrinology (2023).